Benchmark Maintains Buy on Emergent BioSolutions, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman maintains a Buy rating on Emergent BioSolutions (NYSE:EBS) and raises the price target from $5 to $8.
June 20, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman maintains a Buy rating on Emergent BioSolutions and raises the price target from $5 to $8.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100